Ketamine
Enthea, Dr. Bronner’s Post ‘Eye-Opening’ Results from Year-Long Ketamine Trial
Two-thirds of participants with major depressive disorder or generalized anxiety disorder reported improvement.
The post Enthea, Dr. Bronner’s Post ‘Eye-Opening’…
Enthea, a legal insurance provider that covers ketamine-assisted therapy, announced Wednesday that a groundbreaking year-long study that offered treatments to employees of California-based Dr. Bronner’s soap company revealed “eye-opening” results.
The experimental coverage program, which launched in January 2022 as an “ancillary benefit” and had zero cost for Dr. Bronner’s employees, found that only 7% of eligible employees utilized the ketamine regimen, but of those, improvement was observed in:
- 86% with post-traumatic stress disorder
- 67% with major depressive disorder
- 65% with generalized anxiety disorder
“While not everyone experiences such deep healing, many of our team members have reported dramatic improvements in their lives as a result of ketamine-assisted therapy,” David Bronner, the cosmic engagement officer at Dr. Bronner’s, said in a statement.
The ketamine treatments were overseen by San Diego-based Flow Integrative.
Based on the results, Enthea partnered with yet another employer interested in adding similar psychedelic offerings to its employee benefit package: mental wellness provider Nue Life. The partnership will offer telemedicine and at-home treatment models for those interested in ketamine regimens.
The new partnership “begins with a limited rollout that will allow patients to be safely and conveniently treated in the comfort of their own homes,” according to a press release.
Ketamine-assisted therapies often “support improved productivity, increase employee retention rates, lower medical costs, and a more engaged workforce overall,” Enthea asserted in its release.
The cost of such treatments is still a major obstacle for many, since most insurers won’t cover psychedelic treatments. Ketamine-assisted therapy typically costs into the range of $750 to $1,000 per session. And patients typically need four to six sessions, according to a report from Water Tower Research.
But a spokesperson for Enthea confirmed that none of the Dr. Bronner’s employees had to pay any amount out of pocket thanks to the insurance coverage.
“All treatments were 100% covered by Dr. Bronner’s,” the spokesperson wrote in an email to Green Market Report.
The post Enthea, Dr. Bronner’s Post ‘Eye-Opening’ Results from Year-Long Ketamine Trial appeared first on Green Market Report.
ketamine psychedelic therapy major depressive disorder depressive disorder anxiety research-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID